New data includes a study in over 5,000 patients—the largest intragastric balloon weight loss study ever conducted

Allurion (NYSE: ALUR), a company dedicated to ending obesity, today announced the acceptance of nine scientific presentations at the upcoming 26th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). These presentations consist of four abstracts that will be presented as oral presentations, four abstracts that will be presented as posters, and one moderated presentation. IFSO takes place in Naples, Italy, from August 30 to September 1.

Presentations will include data from a global study in over 5,000 patients treated with the Allurion Program, data on combining weight-loss drugs with the Allurion Program, and data on the impact of the Allurion Program on diabetes.

"We are pleased to have the opportunity to present this data at such a prestigious forum. I believe these abstracts will further demonstrate that the Allurion Program can offer a scalable weight loss solution that can be combined with newer weight loss drugs and also have a significant impact on co-morbidities like diabetes,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.

Details of the oral presentations are as follows:

Title: Effectiveness of Semaglutide for the Management of Weight following Sleeve Gastrectomy and Intra Gastric Balloon Therapy Presenter: Mohammad Jamal, M.D., Kuwait University Presentation Date: Wednesday, August 30th, 13:12-13:19

Title: Resolution of Diabetes with Swallowable Balloon Therapy Presenter: Mohit Bhandari, M.D., Founder and Director, Mohak Bariatrics and Robotics Presentation Date: Wednesday, August 30th, 15:35-15:42

Title: The Swallowable Gastric Balloon: Global Experience in 5003 Consecutive Patients – The Largest Gastric Balloon Study in the World Presenter: Roberta Ienca, M.D., Weight Management Center, Nuova Villa Claudia Clinic Presentation Date: Wednesday, August 30th, 15:49-15:56

Title: Swallowable Intragastric Balloons: First Argentinian Experience Presenter: Mariano Palermo, M.D., Director of Bariatric Surgery, Centro CIEN – DIAGNOMED Presentation Date: Wednesday, August 30th, 15:56-16:03

Title: The swallowable balloon – professional treatment of obesity or preventive life-style intervention that anyone can apply? Presenter: Mohit Bhandari, M.D., Founder and Director, Mohak Bariatrics and Robotics Presentation Date: Thursday, August 31st, 09:10-09:20

Details of the poster presentations are as follows:

Title: Can endoscopic procedures like balloons and endoscopic sleeve gastroplasty help in increasing bariatric surgery practice? Presenter: Mohit Bhandari, M.D., Founder and Director, Mohak Bariatrics and Robotics Poster: P-56

Title: Combination therapy of GLP-1 analogues with Swallowable Balloon for treatment of obesity Presenter: Winni Mathur, Mohak Bariatrics and Robotics Poster: P-68

Title: Integrated approach for patients with overweight and obesity treated with swallowable intragastric balloon Presenter: Salvatore Avallone, M.D., Clinique Cap D’Or Poster: P-197

Title: Outcomes of a Swallowable Intragastric Balloon on 96 Overweight and Obese Patients Presenter: Mahmoud Abdelaal, M.D., Assiut University Hospital Poster: P-273

For more information about IFSO, please visit: https://www.ifso2023.org/.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding Allurion’s expectations for, and market acceptance of, the Allurion Program. They reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain regulatory approval for and successfully commercialize the Allurion Program, (ii) the results of clinical data from its studies, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities and (vii) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the proxy statement/prospectus contained in Allurion’s Registration Statement on Form S-4 (333-271862), the company’s Form 8-K filed on August 7, 2023 (as amended), and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

Media Contacts Global Cedric Damour PR Manager +33 7 84 21 02 20 cdamour@allurion.com

USA Erik Milster SeriesM PR 508.740.6125 emilster@seriesmpr.com

Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Allurion Technologies Charts.
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Allurion Technologies Charts.